Enzypad

Our product allows for ambulant multi-parameter blood coagulation analysis.

Our ENZYPAD handheld micro-laboratory will allow the monitoring of the blood coagulation status of any patient anywhere in the world, enabling fast action to prevent or stop bleeds.

Challenge

The challenge is to make a truly portable device, with a cartridge that includes reagents to perform a number of clinically relevant tests, including controls, that has the same quality as tests performed in a specialized hospital laboratory at equivalent costs. Furthermore, the results need to be made available to the attending physician whether he or she is on location or in hospital.

Solution

ENZYCARDs are small microfluidic cartridges that slide into the ENZYPAD processor and contain all the reagents and controls to perform up to sixteen reactions. The first ENZYPAD products will be focused on blood coagulation, the core expertise of the company. The technology can however be applied more broadly in collaboration with partners with expertise in different fields.

Market potential

The first target market for the ENZYPAD technology is Hemophilia patients to monitor their blood coagulation. This well-defined patient population is well aware of the bleeding risks and associated complications that clearly require to have more frequent analysis of blood coagulation so therapy can be adjusted timely. We estimate this market to be about €120M.

Challenge

The challenge is to make a truly portable device, with a cartridge that includes reagents to perform a number of clinically relevant tests, including controls, that has the same quality as tests performed in a specialized hospital laboratory at equivalent costs. Furthermore, the results need to be made available to the attending physician whether he or she is on location or in hospital.

Market potential

The first target market for the ENZYPAD technology is Hemophilia patients to monitor their blood coagulation. This well-defined patient population is well aware of the bleeding risks and associated complications that clearly require to have more frequent analysis of blood coagulation so therapy can be adjusted timely. We estimate this market to be about €120M.

Solution

ENZYCARDs are small microfluidic cartridges that slide into the ENZYPAD processor and contain all the reagents and controls to perform up to sixteen reactions. The first ENZYPAD products will be focused on blood coagulation, the core expertise of the company. The technology can however be applied more broadly in collaboration with partners with expertise in different fields.

How it works

ENZYPAD uses sub-microliter volumes, chemiluminescent technology in combination with high performance nano-optical sensors allowing the desired quality at the acceptable costs. The test results are immediately encrypted and transferred to the cloud where anyone with the appropriate credentials can access them.

Business Cases

Three business cases have been identified for the device: haemophilia treatment management, haemodynamic monitoring in the operating room, intensive care unit & emergency room and oral anti-coagulant monitoring.

Competitive Advantage

ENZYCARDs use proprietary substrates that can be processed by luciferase and generate light when cleaved. Patents to this technology have been granted in EU, US & JP. By using chemiluminescent technology in combination with nano-optical sensors, there is no need for a light source or filters allowing the reduction of the size of the instrument. In turn, this allows the use of microfluidic channels and sub-microliter reagent reservoirs that enable to run up to sixteen assays in a single device.

What this means...

For patients and their families: Better quality of life

Enzypad means certainty about patients’ individual risk to develop a bleed. Analysis can be performed when the need arises. There is no more need to travel to the clinic to manage their disease. This ensures greater mental comfort, as they will have great control of their disease. It also means less complications due to optimized treatment.

For physicians and health care workers: data-based medicine

With Enzypad, physicians and healthcare workers can provide better care without additional effort. It also allows them to manage the patient’s anomaly based on patient real-time data. Lastly, they are able to help more patients through telemedicine.

For pharmaceutical companies: personalized medicine

Pharmaceutical companies can offer optimized therapy, causing increased customer satisfaction. They can retain and/or increase market share, and increase the TAM for the therapy to regions where access to lab-based tests is limited.

For insurance companies: lower costs and optimized treatment

Optimized therapy means less complications and less hospital visits. Also, one doctor can help more patients.

Join us on our journey

Enzyre is now preparing to raise €10M in its Series A investment round. The proceeds will be used to (a) finalize the development of the ENZYPAD en ENZYCARD Hemophilia A, (b) manufacture the portable instrument & disposable, and (c) perform studies to obtain regulatory approval in EU & US. The product will be commercialized worldwide through our pharma partner. Interested candidate investors are encouraged to contact us at investors@enzyre.com.

Get involved